Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pathogen reduction for DoD

This article was originally published in The Gray Sheet

Executive Summary

Navigant Biotechnologies receives $2 mil. from the U.S. Department of Defense for development of Mirasol riboflavin-based pathogen reduction technology for red blood cells. The funding was included in DoD's 2004 $317.2 bil. budget, signed Sept. 30. Walter Reed Army Institute of Research will participate in development of Mirasol, which is slated to enter Phase I trials in early 2004 (1"The Gray Sheet" Sept. 8, 2003, p. 14)...

You may also be interested in...

Navigant Pathogen Inactivation System Catching Up With Cerus, Vitex

Navigant Biotechnologies is dedicating $10 mil. in 2004 to the development of its Mirasol riboflavin-based pathogen reduction technology (PRT) for platelets and red blood cells

Cerus Pathogen Inactivation Trial Delay Alters Landscape For Vitex, Navigant

Uncertainty over Baxter/Cerus' Intercept red blood cell pathogen reduction program may benefit competitor Vitex, which is pursuing the same indication for its Inactine device

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts